Prevention: Protecting Your Family and Community
At a Glance
Preventing Chikungunya involves mosquito control and vaccination for eligible adults. The FDA-approved Ixchiq vaccine offers long-lasting protection for those at risk, while using EPA-registered repellents and eliminating standing water provides essential defense for the whole family.
As someone currently fighting or recovering from Chikungunya, you already know the heavy toll this virus takes. The good news is that once you recover, your body has built strong defenses, and you are generally considered to have lifelong immunity against catching it again [1].
However, you likely want to know how to protect your uninfected family members, your neighbors, and your community. Preventing Chikungunya requires a two-pronged approach: blocking the “delivery system” (mosquitoes) and building internal defenses through vaccination for those who are eligible [2][3].
The Ixchiq Vaccine (VLA1553)
In 2023, the FDA approved Ixchiq, the first vaccine designed to prevent Chikungunya [2]. You do not need this vaccine if you have already been infected, but it may be highly beneficial for uninfected adults in your household or those planning travel to endemic regions.
- How it Works: Ixchiq is a live-attenuated vaccine [4]. This means it contains a weakened version of the live virus that cannot cause the full disease but “teaches” the immune system to recognize and fight the real virus [5][6].
- Effectiveness: A single dose has been shown to produce high levels of protective antibodies that remain effective for at least two years [7][8].
- Eligibility: It is currently approved for adults aged 18 and older who are at increased risk of exposure to the virus [2].
Vaccine Safety Considerations
Because Ixchiq uses a live (though weakened) virus, it is not suitable for everyone.
- The Elderly (65+): Older adults should consult carefully with a doctor. The FDA warns that individuals over 65 have a higher risk of experiencing severe, prolonged Chikungunya-like adverse reactions (such as debilitating joint pain lasting for weeks) after receiving the vaccine [9][10].
- Immunocompromised Individuals: People with weakened immune systems (due to HIV, cancer treatment, or organ transplants) are generally advised against live vaccines [11]. There is a theoretical risk that the weakened virus could replicate uncontrollably if the immune system is not strong enough to keep it in check [11].
- Pregnancy: Live vaccines are typically avoided during pregnancy because of the risk that the virus could pass to the fetus [12][13].
Your Primary Defense: Mosquito Avoidance
Whether your family is vaccinated or not, preventing mosquito bites is the absolute most effective way to avoid Chikungunya, as well as “look-alike” diseases like Dengue and Zika [14][3]. If you are currently in the first week of infection, preventing mosquito bites on yourself protects your community, as mosquitoes cannot spread the virus unless they bite an infected person first.
Personal Protection
- Use EPA-Registered Repellents: Look for products containing DEET, Picaridin, IR3535, or Oil of Lemon Eucalyptus [14]. These are the most effective at deterring Aedes mosquitoes, which bite primarily during the day [3].
- Dress Defensively: Wear long-sleeved shirts and long pants. Treating clothing with permethrin (an insecticide) provides an extra layer of protection that lasts through several washes [3].
Environmental Control
The mosquitoes that carry Chikungunya breed in very small amounts of water. You can significantly reduce the local mosquito population by:
Common questions in this guide
Can I get Chikungunya twice?
Is there a vaccine for Chikungunya?
Who should avoid getting the Chikungunya vaccine?
How can I protect my family from Chikungunya if they are not vaccinated?
Why do I need to avoid mosquito bites if I am already infected with Chikungunya?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Is the Ixchiq vaccine appropriate for my family members who are currently uninfected but at risk?
- 2.Given that Ixchiq is a live-attenuated vaccine, what are the specific risks for elderly relatives over 65?
- 3.Does the vaccine protect against all strains of Chikungunya, or do we still need to be just as careful with mosquito protection?
- 4.Are there any contraindications between this vaccine and other travel vaccines my family might need, like Yellow Fever?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Diagnostic utility of real-time RT-PCR for chikungunya virus detection in the acute phase of infection: a retrospective study.
Sajith A, Iyengar V, Varamballi P, et al.
Annals of medicine 2025; (57(1)):2523559 doi:10.1080/07853890.2025.2523559.
PMID: 40570284 - 2
Live-attenuated chikungunya virus vaccine.
Ng LFP, Rénia L
Cell 2024; (187(4)):813-813.e1 doi:10.1016/j.cell.2024.01.033.
PMID: 38364787 - 3
Chikungunya virus in Europe: A retrospective epidemiology study from 2007 to 2023.
Liu Q, Shen H, Gu L, et al.
PLoS neglected tropical diseases 2025; (19(3)):e0012904 doi:10.1371/journal.pntd.0012904.
PMID: 40053531 - 4
From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.
Chen LH, Fritzer A, Hochreiter R, et al.
Journal of travel medicine 2024; (31(7)) doi:10.1093/jtm/taae123.
PMID: 39255380 - 5
Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.
Kosulin K, Brasel TL, Smith J, et al.
Emerging microbes & infections 2025; (14(1)):2469653 doi:10.1080/22221751.2025.2469653.
PMID: 39998495 - 6
The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection.
Weber WC, Streblow ZJ, Kreklywich CN, et al.
Vaccines 2024; (12(8)) doi:10.3390/vaccines12080893.
PMID: 39204019 - 7
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.
McMahon R, Toepfer S, Sattler N, et al.
The Lancet. Infectious diseases 2024; (24(12)):1383-1392 doi:10.1016/S1473-3099(24)00357-8.
PMID: 39146946 - 8
Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.
Buerger V, Maurer G, Kosulin K, et al.
Journal of travel medicine 2024; (31(7)) doi:10.1093/jtm/taae084.
PMID: 38959854 - 9
Fatal Adverse Event After VLA1553 Chikungunya Vaccination in an Elderly Patient: A Case Report From Reunion Island.
Mosnier E, Jaffar-Bandjee MC, Cally R, et al.
Open forum infectious diseases 2025; (12(9)):ofaf550 doi:10.1093/ofid/ofaf550.
PMID: 40980573 - 10
Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis.
Gervais A, Bastard P, Zhang Q, et al.
Proceedings of the National Academy of Sciences of the United States of America 2026; (123(4)):e2532212123 doi:10.1073/pnas.2532212123.
PMID: 41570068 - 11
Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan.
Kamei K, Miyairi I, Shoji K, et al.
European journal of pediatrics 2021; (180(6)):1847-1854 doi:10.1007/s00431-021-03927-1.
PMID: 33523302 - 12
Pregnant Women Hospitalized with Chikungunya Virus Infection, Colombia, 2015.
Escobar M, Nieto AJ, Loaiza-Osorio S, et al.
Emerging infectious diseases 2017; (23(11)) doi:10.3201/eid2311.170480.
PMID: 29047427 - 13
Rheumatic Manifestations in Patients with Chikungunya Infection: Comment on the Article by Arroyo-Ávila and Vilá.
Sánchez-Duque JA, Orozco-Hernández JP, Rodríguez-Morales AJ
Puerto Rico health sciences journal 2015; (34(4)):231-2.
PMID: 26710364 - 14
Increased threat of urban arboviral diseases from Aedes aegypti mosquitoes in Colombia.
Ramírez RMG, Bohers C, Mousson L, et al.
IJID regions 2024; (11()):100360 doi:10.1016/j.ijregi.2024.100360.
PMID: 38596820
This page provides general information on Chikungunya prevention and the Ixchiq vaccine. Always consult your healthcare provider or travel medicine specialist to determine if vaccination is appropriate for your family members.
Get notified when new evidence is published on Chikungunya.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.